A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
A phase 3 trial of Relugolix in endometrial cancer, run by Sumitomo Pharma Switzerland GmbH, now recruiting.
Overview
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis is a phase 3 interventional study registered as NCT05862272 by Sumitomo Pharma Switzerland GmbH, with 1000 participants planned, started 2023-08-14 and due to reach its primary completion in 2029-07. Interventions recorded: Relugolix Combination Tablet.
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
Shares Endometrial cancer and the tag pipeline.
- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Endometrial cancer and the tag pipeline.
- TrialA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Shares Endometrial cancer and the tag pipeline.
- TrialPsilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Shares Endometrial cancer and the tag pipeline.
- TrialA Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Shares Endometrial cancer and the tag pipeline.
- TrialA Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
Shares Endometrial cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
Shares Endometrial cancer and the tag pipeline.
- TrialA Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Shares Endometrial cancer and the tag pipeline.